The short version of heptapeptide fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-04-01 and is reviewed periodically as new material appears.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H68N10O14 | Acetylated heptapeptide form |
| Monoisotopic mass | 888.5 Da | Average mass about 889 Da |
| Appearance | White to off-white solid | Usually supplied as lyophilised powder |
| Solubility class | Highly water soluble | Also dissolves in aqueous buffers |
| Common synonyms | Tbeta4 fragment, thymosin beta-4 (17-23) | Refer to the same sequence |
Reconstitution of a lyophilized peptide is normally done with sterile water or a suitable buffer under aseptic conditions. Adding solvent down the vial wall and allowing gentle dissolution instead of vigorous vortexing reduces the chance of aggregation, which can lower the effective concentration of the resulting solution. Concentrated stocks are usually diluted into working buffer shortly before use. Because no standard preparation protocol exists for TB-500 specifically, laboratories adapt general peptide handling practice, and reported results may reflect differing preparation choices.
Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.
Peptide bonds are susceptible to hydrolysis under extreme pH and to enzymatic cleavage if proteases are present. Heat, oxidising agents, and prolonged exposure to light also contribute to loss of material. Aggregation can occur at high concentrations or in certain buffer systems, and it may not be visible to the eye. Storage at -20 C or below is typical for both powder and aliquoted solutions, and desiccation of the powder is preferred.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography together with mass spectrometry. The chromatogram provides a purity estimate as a percentage of total peak area, while the mass spectrum confirms that the observed mass matches the expected value. Amino acid analysis or tandem mass spectrometry sequencing can provide additional confirmation. Reported purity figures depend on the column, gradient, and detection wavelength, so values from different laboratories are not directly comparable without method details.
Purity is normally assessed by reversed-phase HPLC, with the main peak reported as a percentage of total peak area, while identity is confirmed by mass spectrometry. Electrospray and MALDI-TOF instruments are both used, and the observed mass is compared with the value calculated from the stated sequence. Ion-exchange or size-exclusion methods appear where aggregation or charge variants are of interest. Water content, counter-ion content and residual trifluoroacetate from purification are separate variables that can shift the measured mass and should be weighed when reading a certificate of analysis.
Research peptides are typically supplied as a white to off-white lyophilised powder in a sealed vial. The dry solid is more stable than a solution and is normally kept refrigerated or frozen until use. Dissolution is usually done in water, phosphate-buffered saline or a similar aqueous medium, depending on the assay. Because the material is hygroscopic and easily contaminated, opening vials in a low-humidity environment and recording the lot number before use are standard laboratory practices.
Once in solution, short peptides are generally less stable than the dry powder, and repeated freeze-thaw cycles are a common cause of loss. Laboratory guidance usually calls for aliquoting on first dissolution and storing aliquots at -20 °C or below, away from light. Adsorption to plastic and glass surfaces can lower measured concentration, particularly at low concentrations, so container material and buffer choice can affect results. Visible cloudiness, colour change or unexpected precipitate is a signal to re-check the material.
The reactor was built with spare fuel channels that were then used to increase the normal operating levels of the reactor, thus increasing the burn-up rate of the accumulating 135Xe. Reactors with large physical dimensions, e.g. the RBMK type, can develop significant nonuniformities of xenon concentration through the core. Control of such non-homogeneously poisoned cores, especially at low power, is a challenging problem. The Chernobyl disaster occurred after recovering Reactor 4 from a nonuniformly poisoned state. Reactor power was significantly reduced in preparation for a test, to be followed by a scheduled shutdown. Just before the test, the power plummeted in part due to the accumulation of 135Xe as a result of the low burn-up rate at low power. Operators withdrew most of the control rods in an attempt to bring the power back up. Unbeknownst to the operators, these and other actions put the reactor in a state where it was exposed to a feedback loop of neutron power and steam production. A flawed shutdown system then caused a power surge that led to the explosion and destruction of reactor 4. The iodine pit effect has to be taken in account for reactor designs. High values of power density, leading to high production rates of fission products and therefore higher iodine concentrations, require higher amount and enrichment of the nuclear fuel used to compensate.
== Personal life == Freeman came to Australia with his parents and his sister, Eva. Following the death of his father in 1958, he became a Director of K. H. Freeman Pty Ltd, which continues to operate today. He met Edith Siou in 1964 and they married in 1966. They have two children, Maeva and Philip.
== Philanthropy == In September 2014, Jimmy John's donated $1 million to the Folds of Honor Foundation, a foundation that supports the families of killed or disabled soldiers. During the 2015 school year, Jimmy John's donated more than 100 laptop computers to the Champaign Unit 4 School District. Jimmy John's donated $125,000 to the Champaign Parks Foundation to support the Youth Scholarship Program in November 2016. In June 2017, Jimmy John's donated $100,000 to EAT (RED) SAVE LIVES to offer HIV/AIDS medication in sub-Saharan Africa. In December 2018, Jimmy John's donated $80,000 to pay off all Christmas layaways at Walmart in Champaign, Urbana, and Savoy.
Sources: en.wikipedia.org
It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication. In 2023, it was the 52nd most commonly prescribed medication in the United States, with more than 12 million prescriptions. Spironolactone has a history of use in the trans community. Its use continues despite the rise of various accessible alternatives such as bicalutamide and cyproterone acetate with more precise action and fewer side effects.
are calculated for a short time frame, and the matrices for longer periods of time are calculated by assuming mutations follow a Markov chain model. The base unit of time for the PAM matrices is the time required for 1 mutation to occur per 100 amino acids, sometimes called 'a PAM unit' or 'a PAM' of time. This is precisely the duration of mutation assumed by the PAM1 matrix. The constant
On 16 April 1973, Gaddafi proclaimed the start of a "Popular Revolution" in a speech at Zuwarah. He initiated this with a five-point plan, the first point of which dissolved all existing laws, to be replaced by revolutionary enactments. The second point proclaimed that all opponents of the revolution had to be removed, while the third initiated an administrative revolution that Gaddafi proclaimed would remove all traces of bureaucracy and the bourgeoisie. The fourth point announced that the population must form People's Committees and be armed to defend the revolution, while the fifth proclaimed the beginning of the Cultural Revolution in Libya, to expunge the country of "poisonous" foreign influences. He began to lecture on this new phase of the revolution in Libya, Egypt, and France. As a process, it had many similarities with the Cultural Revolution implemented in China. As part of this Popular Revolution, Gaddafi invited Libya's people to found General People's Committees as conduits for raising political consciousness. Although offering little guidance for how to set up these councils, Gaddafi claimed that they would offer a form of direct political participation that was more democratic than a traditional party-based representative system. He hoped that the councils would mobilize the people behind the RCC, erode the power of the traditional leaders and the bureaucracy, and allow for a new legal system chosen by the people.
Sources: en.wikipedia.org
No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.
It consists of leucine, lysine, lysine, threonine, glutamic acid, threonine, and glutamine in that order. The N-terminal leucine is usually acetylated in the forms described in catalogues.
Controlled human data is limited, and most published findings come from cell culture or animal work. This makes it difficult to state clinical effects with confidence.
No. TB-500 is a trade-style label used for a synthetic peptide described as a fragment of thymosin beta-4, while thymosin beta-4 is the full 43-residue protein. The two differ in size and are not interchangeable terms in analytical work.